Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine
暂无分享,去创建一个
M. Ingelman-Sundberg | L. Bertilsson | U. Meyer | M. Heim | I. Johansson | M. Dahl | F. Sjöqvist | Q. Yue | J. Säwe
[1] U. Meyer,et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. , 1990, The Journal of biological chemistry.
[2] U. Meyer,et al. Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.
[3] U. Meyer,et al. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934----A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3' splice recognition site. , 1990, American journal of human genetics.
[4] L. Pickle,et al. DEBRISOQUINE PHENOTYPE AND GENOTYPE IN CHINESE , 1989, The Lancet.
[5] C. Alm,et al. Interindividual and interethnic differences in the demethylation and glucuronidation of codeine. , 1989, British journal of clinical pharmacology.
[6] C. Alm,et al. Codeine O-demethylation co-segregates with polymorphic debrisoquine hydroxylation. , 1989, British journal of clinical pharmacology.
[7] M. Ingelman-Sundberg,et al. DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE , 1989, The Lancet.
[8] T. Ishizaki,et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese , 1989, Clinical pharmacology and therapeutics.
[9] L. Bertilsson,et al. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects , 1988, Clinical pharmacology and therapeutics.
[10] U. Meyer,et al. Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.
[11] R. Skoda,et al. Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[12] L. Bertilsson,et al. LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION , 1987, The Lancet.
[13] M. Eichelbaum,et al. Evidence for polymorphic oxidation of sparteine in Japanese subjects. , 1987, British journal of clinical pharmacology.
[14] R. Branch,et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.
[15] J. Idle,et al. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.
[16] M. Eichelbaum,et al. Defective N-oxidation of sparteine in man: A new pharmacogenetic defect , 1979, European Journal of Clinical Pharmacology.
[17] G. Tucker,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE , 1977, The Lancet.
[18] J. Idle,et al. POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.
[19] K. Brøsen,et al. Clinical significance of the sparteine/debrisoquine oxidation polymorphism , 2004, European Journal of Clinical Pharmacology.
[20] A. S. Gross,et al. The genetic polymorphism of debrisoquine/sparteine metabolism--clinical aspects. , 1990, Pharmacology & therapeutics.